High dose Epirubicin is effective in measurable metastatic prostate cancer : a phase II study of the EORTC genitourinary group

Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07).

Cathomas, R.
Rothermundt, C.
Klingbiel, D.
Bubendorf, L.
Jaggi, R.
Betticher, D.C.
Brauchli, P.
Cotting, D.
Droege, C.
Winterhalder, R.
Siciliano, D.
Berthold, D.R.
Pless, M.
Schiess, R.
von Moos, R.
Gillessen, S.

January 2012

PURPOSE: The EGF receptor (EGFR) is overexpressed in the majority of metastatic castration-resistant...

Phase II study of epirubicin in advanced adenocarcinoma of the pancreas

Wils, Jaques
Bleiberg, Harry
Blijham, Geert
Dalesio, Otilia
Duez, Nicole
Lacave, Ángel Jiménez
Splinter, Ted

January 1985

The EORTC Gastrointestinal Group has conducted a phase II trial in 41 patients with locally advanced...

Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy

Mulders, P.F.A.
Santis, M. de
Powles, T.
Fizazi, K.

January 2015

Contains fulltext : 154085.pdf (Publisher’s version ) (Open Access)CONTEXT: Prosta...

High-dose Epirubicin Is Effective in Measurable Metastatic Prostate-cancer - a Phase-ii Study of the Eortc Genitourinary Group

Brausi, M.
Jones, WG.
Fossa, SD.
Demulder, PHM.
Droz, JP.
Lentz, MA.
Vanglabbeke, M.
Pawinski, A.

January 1995

39 hormone-resistant prostate cancer patients with bidimensionally measurable metastatic lesions wer...

Results of a phase II trial of epirubicin and cisplatin (EP) before and after irradiation and 5-fluorouracil in locally advanced pancreatic cancer : an EORTC GITCCG study

Wagener, D.J.T.
Hoogenraad, W.J.
Rougier, P.
Lusinchi, A.
Taal, B.G.
Veenhof, C.H.N.
Graeff, A. de
Conroy, T.
Curran, D.
Sahmoud, T.
Wils, J.

January 1996

Contains fulltext : 22915___.PDF (publisher's version ) (Open Access

Epirubicin in colorectal cancer - A phase II study of the early clinical trials group (EORTC)

Holdener, Eduard E.E.
Hansen, Heine
Høst, Hans
Bruntsch, Uta
Cavalli, Franco
Renard, Josette
Pinedo, Herbert H.M.
Rozencweig, Marcel

March 1985

Epirubicin, a stereoisomer of doxorubicin with suggested lower potential for cardiotoxicity in exper...

EORTC (30885) randomised phase III study with recombinant interferon alpha and recombinant interferon alpha and gamma in patients with advanced renal cell carcinoma

Mulder, P.H.M. de
Oosterhof, G.O.N.
Bouffioux, C.
Oosterom, R.
Vermeylen, K.
Sylvester, R.J.

January 1995

Contains fulltext : 21855___.PDF (publisher's version ) (Open Access

High-dose 5-fluorouracil and leucovorin as second-line chemotherapy in patients with platinum-resistant epithelial ovarian cancer

Kamphuis, J.T.
Huider, M.C.
Ras, G.J.
Verhagen, C.A.H.H.V.
Kateman, I.
Vreeswijk, J.H.A.
Burghouts, J.T.M.

January 1995

Contains fulltext : 22176___.PDF (publisher's version ) (Open Access

The importance of targeting intracrinology in prostate cancer management

Hamid, A.
Tendi, W.
Sesari, S.S.
Mochtar, C.A.
Umbas, R.
Verhaegh, G.W.
Schalken, J.A.

January 2019

Contains fulltext : 204684.pdf (publisher's version ) (Closed access)Accumulating ...

Short Androgen Suppression and Radiation Dose Escalation for Intermediate- and High-Risk Localized Prostate Cancer: Results of EORTC Trial 22991

Bolla, M.
Maingon, P.
Carrie, C.
Villa, S.
Kitsios, P.
Poortmans, P.M.P.
Sundar, S.
Steen-Banasik, E.M. van der
Armstrong, J.
Bosset, J.F.
Herrera, F.G.
Pieters, B.
Slot, A.
Bahl, A.
Ben-Yosef, R.
Boehmer, D.
Scrase, C.
Renard, L.
Shash, E.
Coens, C.
Bergh, A.C. van den
Collette, L.

January 2016

Item does not contain fulltextPURPOSE: Up to 30% of patients who undergo radiation for intermediate-...

Weekly epirubicin in patients with hormone-resistant prostate cancer.

Petrioli R
Fiaschi AI
Pozzessere D
Messinese S
Sabatino M
Marsili S
Correale P
Manganelli A
Salvestrini F
Francini G.

January 2002

The aim of this study was to investigate the benefit of weekly epirubicin in the treatment of metast...

Phase IB study of doxorubicin in combination with the multidrug resistance reversing agent S9788 in advanced colorectal and renal cell cancer

Punt, C.J.A.
Voest, E.E.
Tueni, E.
Oosterom, A. van
Backx, A.P.C.M.
Mulder, P.H.M. de
Hecquet, B.
Lucas, C.
Gerard, B.
Bleiberg, H.

January 1997

Contains fulltext : 24647___.PDF (publisher's version ) (Open Access

Gemcitabine: a phase II study in patients with advanced renal cancer

Mulder, P.H.M. de
Weissbach, L.
Jakse, G.
Osieka, R.
Blatter, J.

January 1996

Contains fulltext : 23938___.PDF (publisher's version ) (Open Access

A randomized study comparing epirubicin in a 4-weekly versus a weekly intravenous regimen in patients with metastatic, hormone resistant, prostatic carcinoma: effects on health related quality of life.

Andel, G. van
Fernandez del Moral, P.
Caris, C.T.M.
Carpentier, P.
Wils, J.
Bruin, M.J. de
Witjes, J.A.
Debruyne, F.M.J.
Witjes, W.P.J.

January 2003

The treatment of hormone resistant prostate cancer) with epirubicin 25 mg/m(2)(Epi25) on a weekly in...

Results from a Phase I Study of Lapatinib with Gemcitabine and Cisplatin in Advanced or Metastatic Bladder Cancer: EORTC Trial 30061

Cerbone, L.
Sternberg, C.N.
Sengelov, L.
Agerbaek, M.
Herpen, C.M.L. van
Marreaud, S.
Collette, S.
Zhang, J.
Daugaard, G.

January 2016

Contains fulltext : 171411.pdf (publisher's version ) (Closed access)BACKGROUND/OB...

Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07).

Cathomas, R.
Rothermundt, C.
Klingbiel, D.
Bubendorf, L.
Jaggi, R.
Betticher, D.C.
Brauchli, P.
Cotting, D.
Droege, C.
Winterhalder, R.
Siciliano, D.
Berthold, D.R.
Pless, M.
Schiess, R.
von Moos, R.
Gillessen, S.

January 2012

PURPOSE: The EGF receptor (EGFR) is overexpressed in the majority of metastatic castration-resistant...

Phase II study of epirubicin in advanced adenocarcinoma of the pancreas

Wils, Jaques
Bleiberg, Harry
Blijham, Geert
Dalesio, Otilia
Duez, Nicole
Lacave, Ángel Jiménez
Splinter, Ted

January 1985

The EORTC Gastrointestinal Group has conducted a phase II trial in 41 patients with locally advanced...

Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy

Mulders, P.F.A.
Santis, M. de
Powles, T.
Fizazi, K.

January 2015

Contains fulltext : 154085.pdf (Publisher’s version ) (Open Access)CONTEXT: Prosta...

High-dose Epirubicin Is Effective in Measurable Metastatic Prostate-cancer - a Phase-ii Study of the Eortc Genitourinary Group

Brausi, M.
Jones, WG.
Fossa, SD.
Demulder, PHM.
Droz, JP.
Lentz, MA.
Vanglabbeke, M.
Pawinski, A.

January 1995

39 hormone-resistant prostate cancer patients with bidimensionally measurable metastatic lesions wer...

Results of a phase II trial of epirubicin and cisplatin (EP) before and after irradiation and 5-fluorouracil in locally advanced pancreatic cancer : an EORTC GITCCG study

Wagener, D.J.T.
Hoogenraad, W.J.
Rougier, P.
Lusinchi, A.
Taal, B.G.
Veenhof, C.H.N.
Graeff, A. de
Conroy, T.
Curran, D.
Sahmoud, T.
Wils, J.

January 1996

Contains fulltext : 22915___.PDF (publisher's version ) (Open Access

Epirubicin in colorectal cancer - A phase II study of the early clinical trials group (EORTC)

Holdener, Eduard E.E.
Hansen, Heine
Høst, Hans
Bruntsch, Uta
Cavalli, Franco
Renard, Josette
Pinedo, Herbert H.M.
Rozencweig, Marcel

March 1985

Epirubicin, a stereoisomer of doxorubicin with suggested lower potential for cardiotoxicity in exper...

EORTC (30885) randomised phase III study with recombinant interferon alpha and recombinant interferon alpha and gamma in patients with advanced renal cell carcinoma

Mulder, P.H.M. de
Oosterhof, G.O.N.
Bouffioux, C.
Oosterom, R.
Vermeylen, K.
Sylvester, R.J.

January 1995

Contains fulltext : 21855___.PDF (publisher's version ) (Open Access

High-dose 5-fluorouracil and leucovorin as second-line chemotherapy in patients with platinum-resistant epithelial ovarian cancer

Kamphuis, J.T.
Huider, M.C.
Ras, G.J.
Verhagen, C.A.H.H.V.
Kateman, I.
Vreeswijk, J.H.A.
Burghouts, J.T.M.

January 1995

Contains fulltext : 22176___.PDF (publisher's version ) (Open Access

The importance of targeting intracrinology in prostate cancer management

Hamid, A.
Tendi, W.
Sesari, S.S.
Mochtar, C.A.
Umbas, R.
Verhaegh, G.W.
Schalken, J.A.

January 2019

Contains fulltext : 204684.pdf (publisher's version ) (Closed access)Accumulating ...

Short Androgen Suppression and Radiation Dose Escalation for Intermediate- and High-Risk Localized Prostate Cancer: Results of EORTC Trial 22991

Bolla, M.
Maingon, P.
Carrie, C.
Villa, S.
Kitsios, P.
Poortmans, P.M.P.
Sundar, S.
Steen-Banasik, E.M. van der
Armstrong, J.
Bosset, J.F.
Herrera, F.G.
Pieters, B.
Slot, A.
Bahl, A.
Ben-Yosef, R.
Boehmer, D.
Scrase, C.
Renard, L.
Shash, E.
Coens, C.
Bergh, A.C. van den
Collette, L.

January 2016

Item does not contain fulltextPURPOSE: Up to 30% of patients who undergo radiation for intermediate-...

Weekly epirubicin in patients with hormone-resistant prostate cancer.

Petrioli R
Fiaschi AI
Pozzessere D
Messinese S
Sabatino M
Marsili S
Correale P
Manganelli A
Salvestrini F
Francini G.

January 2002

The aim of this study was to investigate the benefit of weekly epirubicin in the treatment of metast...

Phase IB study of doxorubicin in combination with the multidrug resistance reversing agent S9788 in advanced colorectal and renal cell cancer

Punt, C.J.A.
Voest, E.E.
Tueni, E.
Oosterom, A. van
Backx, A.P.C.M.
Mulder, P.H.M. de
Hecquet, B.
Lucas, C.
Gerard, B.
Bleiberg, H.

January 1997

Contains fulltext : 24647___.PDF (publisher's version ) (Open Access

Gemcitabine: a phase II study in patients with advanced renal cancer

Mulder, P.H.M. de
Weissbach, L.
Jakse, G.
Osieka, R.
Blatter, J.

January 1996

Contains fulltext : 23938___.PDF (publisher's version ) (Open Access

A randomized study comparing epirubicin in a 4-weekly versus a weekly intravenous regimen in patients with metastatic, hormone resistant, prostatic carcinoma: effects on health related quality of life.

Andel, G. van
Fernandez del Moral, P.
Caris, C.T.M.
Carpentier, P.
Wils, J.
Bruin, M.J. de
Witjes, J.A.
Debruyne, F.M.J.
Witjes, W.P.J.

January 2003

The treatment of hormone resistant prostate cancer) with epirubicin 25 mg/m(2)(Epi25) on a weekly in...

Results from a Phase I Study of Lapatinib with Gemcitabine and Cisplatin in Advanced or Metastatic Bladder Cancer: EORTC Trial 30061

Cerbone, L.
Sternberg, C.N.
Sengelov, L.
Agerbaek, M.
Herpen, C.M.L. van
Marreaud, S.
Collette, S.
Zhang, J.
Daugaard, G.

January 2016

Contains fulltext : 171411.pdf (publisher's version ) (Closed access)BACKGROUND/OB...

Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07).

Cathomas, R.
Rothermundt, C.
Klingbiel, D.
Bubendorf, L.
Jaggi, R.
Betticher, D.C.
Brauchli, P.
Cotting, D.
Droege, C.
Winterhalder, R.
Siciliano, D.
Berthold, D.R.
Pless, M.
Schiess, R.
von Moos, R.
Gillessen, S.

January 2012

PURPOSE: The EGF receptor (EGFR) is overexpressed in the majority of metastatic castration-resistant...

Phase II study of epirubicin in advanced adenocarcinoma of the pancreas

Wils, Jaques
Bleiberg, Harry
Blijham, Geert
Dalesio, Otilia
Duez, Nicole
Lacave, Ángel Jiménez
Splinter, Ted

January 1985

The EORTC Gastrointestinal Group has conducted a phase II trial in 41 patients with locally advanced...

Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy

Mulders, P.F.A.
Santis, M. de
Powles, T.
Fizazi, K.

January 2015

Contains fulltext : 154085.pdf (Publisher’s version ) (Open Access)CONTEXT: Prosta...

High dose Epirubicin is effective in measurable metastatic prostate cancer : a phase II study of the EORTC genitourinary group

Abstract

Extracted data

High dose Epirubicin is effective in measurable metastatic prostate cancer : a phase II study of the EORTC genitourinary group

Abstract

Extracted data

Related items

Related items